IRIS
LARONI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.157
Totale 7.157
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.157
Totale 7.157
Salva come PNG Salva come JPEG
Città #
Genova 5.668
Rapallo 781
Genoa 688
Bordighera 20
Totale 7.157
Salva come PNG Salva come JPEG
Nome #
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 185
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 182
Neuroprotective features of mesenchymal stem cells. 168
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 158
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 153
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 147
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 144
Three years of experience: the Italian registry and safety data update 140
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 139
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 126
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 118
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 116
T-cell trafficking in the central nervous system. 114
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. 113
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 110
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 110
Teriflunomide treatment reduces B cells in patients with MS. 109
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis 109
Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity 106
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation 105
Approved drugs for multiple sclerosis: The challenge of choice 104
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod 104
Wernicke's syndrome during parenteral feeding: not an unusual complication. 102
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution 101
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis 100
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 100
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. 99
IL-27 imparts immunoregulatory function to human NK cell subsets. 98
Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma? 98
A case of thyroiditis during natalizumab therapy for multiple sclerosis 97
Mesenchymal stem cells as treatment for MS - progress to date. 96
Can we kill an extra bird with the same stone? 96
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 96
Role of the innate immune system in the pathogenesis of multiple sclerosis. 95
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study 95
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 94
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 92
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 87
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 87
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 85
Epstein-Barr-negative MS: a true phenomenon? 83
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 83
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 82
Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. 82
JCV-DNA testing during natalizumab treatment is complementary to anti-JCV antibodies for PML risk stratification 81
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis 81
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 81
Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. 80
Enhancing natural killer cells is beneficial in multiple sclerosis - Yes 80
Dysregulation of regulatory CD56 (bright) NK cells/T cells interactions in multiple sclerosis 79
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey 78
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL 77
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 75
Long-term disability progression in primary progressive multiple sclerosis: A 15-year study 73
Health-related quality of life in multiple sclerosis: Effects of natalizumab 72
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 67
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 62
Natural killer cells are functionally defective in multiple sclerosis 61
Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection 60
Finger motor performance as a new quantitative clinical endpoint in multiple sclerosis 59
Impaired suppressor function of NK cells in multiple sclerosis 58
Assessing upper limb function in Multiple Sclerosis by an engineered glove 56
CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis 54
Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS 53
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments 50
Nonfunctional natural killer regulatory cells in multiple sclerosis 49
MESEMS: a randomized, double blind placebo-controlled cross-over study to evaluate safety and efficacy of intravenous administration of autologous mesenchymal stem cells in patients with multiple sclerosis 48
Impaired suppressor function of CD56bright NK cells in early multiple sclerosis 48
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 48
Interferon beta potentiates the therapeutic activity of mesenchymal stem cells 44
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 41
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 39
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 39
Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy 38
Cyclophosphamide pulses therapy after natalizumab discontinuation in Multiple Sclerosis patients 35
To switch therapies in RRMS: why and when? A real-life multicentre study. 35
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 35
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 35
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives 34
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 34
Informing MS patients on treatment options: a consensus on the process of consent taking 33
Mesenchymal Stem/Stromal Cells for Multiple Sclerosis and Other Neurological Diseases 32
Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study 32
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 31
Caregiver Involvement in MS: Duty or Disruption? 30
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 30
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 29
Magnetic Resonance Imaging Finding of Periodontal and Inferior Alveolar Nerve Inflammation in a Subject With Trigeminal Neuralgia 26
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab 26
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 23
Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups 22
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial 22
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 21
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 20
A real-world study of alemtuzumab in a cohort of Italian patients 19
A pilot study comparing myelin measurements from [18F]-Florbetaben PET and quantitative T1 map imaging in multiple sclerosis (MS) 15
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: who gains from it? 14
The short-chain fatty acid butyrate decreases the regulatory function of human natural killer cells and promotes their maturation 13
High or increasing serum NfL is predictive of impending multiple sclerosis relapses 13
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis 11
Totale 7.409
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.385
article - articoli 23.050
book - libri 0
conference - conferenze 157
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 178
Totale 46.770
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019480 0 0 0 0 0 0 0 0 0 88 202 190
2019/20202.118 95 79 111 132 175 247 305 188 187 324 228 47
2020/2021880 60 55 57 112 87 54 69 74 55 110 75 72
2021/20221.094 45 28 84 111 44 94 40 252 74 113 66 143
2022/2023960 99 74 15 78 149 163 6 67 171 15 102 21
2023/2024583 41 84 9 88 66 84 53 70 69 19 0 0
Totale 7.474